Murj scoops $8.5M to enable boom in devices and data

A screen from Murj's platform (Murj)

Murj thinks it has spotted a bottleneck in the adoption of implantable cardiac medical devices. With each device and the data it generates adding to the workload of cardiac clinics, the startup sees the burden on clinics becoming too much. Now, Murj has raised $8.5 million to advance its answer to the problem.  

Innovation in the cardiac implant sector is increasing the device options available to patients and the quantity of data they generate. At the same time, demographic and lifestyle changes are increasing the number of patients in the U.S. who need cardiac interventions. The result is that cardiac clinics are handling more patients, devices and data than before.

That is the rationale behind Murj, which has developed a cloud-based workflow intended to lighten the load on clinics. The platform pulls in data on patients and their devices to make it easier for clinics to monitor and process them.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Murj exited from stealth mode with a $4.5 million series A round about one year ago, before going on to unveil its platform the following month. Having picked up customers including Alaska Heart & Vascular Institute, Murj has now gone back to investors for money to support the next stage of its development. 

New backer Longitude Capital stepped up and led the round with the support of True Ventures—the chief contributor to the series A—and other existing investors. Murj will use the money to step up its commercialization of the platform.

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Daré Bioscience added a microchip-based implant to its pipeline and reported data from a pre-pivotal study of a hormone-free contraceptive ring.